News
Displaying 151–160 of 525
-
Foundation Fighting Blindness Announces Leadership Changes
Foundation NewsJason Menzo named chief executive officer • Russell Kelley, PhD, MBA, appointed managing director of the RD Fund • Ben Yerxa, PhD, to lead Opus Genetics, the first RD Fund- and Foundation-backed spin-off company.
-
Research News
The newly approved drug reduces the pathologic hunger associated with BBS
-
In the Press
Funds to support advancement of two clinical trials through proof of concept: NPI-001 for retinitis pigmentosa in Usher syndrome and NPI-002 to slow cataract progression.
-
Over Thirty Presentations Highlighted during the 2022 Retinal Cell & Gene Therapy Innovation Summit
Research NewsIn its seventh year, the Retinal Cell & Gene Therapy Innovation Summit featured 34 presentations from industry experts from around the world.
-
Luxa Doses First Participant in Clinical Trial of RPE Stem Cells for Dry AMD Patients
Research NewsThe company’s RPESC-RPE cell product is composed of progenitor-stage RPE cells grown from human eyes donated to eye banks.
-
ProQR’s Sepofarsen Improves Vision Significantly for Girl with LCA10
Research NewsHowever, the Phase 2/3 Illuminate trial for sepofarsen didn’t meet its endpoints at 12 months
-
AGTC’s XLRP Gene Therapy Performs Well in Extension of Phase 2 Clinical Trial
Research NewsThe three-month results support the planned launch of the company’s Phase 2/3 Vista trial
-
Enhanced Implantable Miniature Telescope Moving into Clinical Trial for AMD Patients
Research NewsThe device is designed for people with late-stage AMD who have no treatment options
-
Opus Genetics Appoints Jennifer Hunt Chief Development Officer
In the PressBiopharma clinical development veteran to propel Opus’ AAV-based gene therapies for inherited retinal diseases toward patients.
-
Foundation Fighting Blindness to Host VISIONS 2022 Conference
Foundation NewsThe national conference will be held on June 17–18, featuring sessions with the latest research advancements, practical adapting and thriving, and an opportunity to connect with the blind and low vision community.
